Rocky Barilla

Rocky Barilla

Auto-generated profile, based on publicly available information

Rocky Barilla

Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women’s Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2016 in Nature
Verified
Journal Article
Open access
PDF file
LSLena Seifert
Lena Seifert
GWGregor Werba
Gregor Werba
STShaun Tiwari
Shaun Tiwari
NLNancy Ngoc Giao Ly
Nancy Ngoc Giao Ly
SASara Alothman
Sara Alothman
GMGeorge Miller
George Miller
A study of pancreatic ductal adenocarcinoma shows that cancer cell proliferation is associated with increased expression of proteins that control programmed necrotic cell death and suppress the adaptive immune system. George Miller and colleagues have investigated the role of programmed necrosis in pancreatic ductal adenocarcinoma (PDA). They observe upregulation of the necrosome factors CXCL1 and Mincle, and this correlates with proliferation of the cancer cells. Furthermore, necroptosis induces signalling pathways that lead to suppression of the adaptive immune system, reinforcing the development of PDA. Neoplastic pancreatic epithelial cells are believed to die through caspase 8-dependent apoptotic cell death, and chemotherapy is thought to promote tumour apoptosis1. Conversely, cancer cells often disrupt apoptosis to survive2,3. Another type of programmed cell death is necroptosis (programmed necrosis), but its role in pancreatic ductal adenocarcinoma (PDA) is unclear. There are many potential inducers of necroptosis in PDA, including ligation of tumour necrosis factor receptor 1 (TNFR1), CD95, TNF-related apoptosis-inducing ligand (TRAIL) receptors, Toll-like receptors, reactive oxygen species, and chemotherapeutic drugs4,5. Here we report that the principal components of the necrosome, receptor-interacting protein (RIP)1 and RIP3, are highly expressed in PDA and are further upregulated by the chemotherapy drug gemcitabine. Blockade of the necrosome in vitro promoted cancer cell proliferation and induced an aggressive oncogenic phenotype. By contrast, in vivo deletion of RIP3 or inhibition of RIP1 protected against oncogenic progression in mice and was associated with the development of a highly immunogenic myeloid and T cell infiltrate. The immune-suppressive tumour microenvironment associated with intact RIP1/RIP3 signalling depended in part on necroptosis-induced expression of the chemokine attractant CXCL1, and CXCL1 blockade protected against PDA. Moreover, cytoplasmic SAP130 (a subunit of the histone deacetylase complex) was expressed in PDA in a RIP1/RIP3-dependent manner, and Mincle—its cognate receptor—was upregulated in tumour-infiltrating myeloid cells. Ligation of Mincle by SAP130 promoted oncogenesis, whereas deletion of Mincle protected against oncogenesis and phenocopied the immunogenic reprogramming of the tumour microenvironment that was induced by RIP3 deletion. Cellular depletion suggested that whereas inhibitory macrophages promote tumorigenesis in PDA, they lose their immune-suppressive effects when RIP3 or Mincle is deleted. Accordingly, T cells, which are not protective against PDA progression in mice with intact RIP3 or Mincle signalling, are reprogrammed into indispensable mediators of anti-tumour immunity in the absence of RIP3 or Mincle. Our work describes parallel networks of necroptosis-induced CXCL1 and Mincle signalling that promote macrophage-induced adaptive immune suppression and thereby enable PDA progression.

10 April 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DDDonnele Daley
Donnele Daley
VMVishnu R Mani
Vishnu R Mani
NMNavyatha Mohan
Navyatha Mohan
NANeha Akkad
Neha Akkad
AOAtsuo Ochi
Atsuo Ochi
GMGeorge Miller
George Miller
Activation of dectin-1-dependent signaling in macrophages through ligation by galectin 9 promotes an immunosuppressive, protumorigenic microenvironment in pancreatic adenocarcinoma (PDA). Blocking dectin 1 ligation restores anti-tumor immunity and delays tumor growth, thus offering a novel strategy for improving the effectiveness of immunotherapy in patients with PDA. The progression of pancreatic oncogenesis requires immune-suppressive inflammation in cooperation with oncogenic mutations. However, the drivers of intratumoral immune tolerance are uncertain. Dectin 1 is an innate immune receptor crucial for anti-fungal immunity, but its role in sterile inflammation and oncogenesis has not been well defined. Furthermore, non-pathogen-derived ligands for dectin 1 have not been characterized. We found that dectin 1 is highly expressed on macrophages in pancreatic ductal adenocarcinoma (PDA). Dectin 1 ligation accelerated the progression of PDA in mice, whereas deletion of Clec7a—the gene encoding dectin 1—or blockade of dectin 1 downstream signaling was protective. We found that dectin 1 can ligate the lectin galectin 9 in mouse and human PDA, which results in tolerogenic macrophage programming and adaptive immune suppression. Upon disruption of the dectin 1–galectin 9 axis, CD4+ and CD8+ T cells, which are dispensable for PDA progression in hosts with an intact signaling axis, become reprogrammed into indispensable mediators of anti-tumor immunity. These data suggest that targeting dectin 1 signaling is an attractive strategy for developing an immunotherapy for PDA.

1 September 2016 in Cell
Verified
Journal Article
Closed access
DDDonnele Daley
Donnele Daley
CZConstantinos Pantelis Zambirinis
Constantinos Pantelis Zambirinis
LSLena Seifert
Lena Seifert
NANeha Akkad
Neha Akkad
NMNavyatha Mohan
Navyatha Mohan
GMGeorge Miller
George Miller

20 August 2012 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AOAtsuo Ochi
Atsuo Ochi
ANAndrew H. Nguyen
Andrew H. Nguyen
ABAndrea S. Bedrosian
Andrea S. Bedrosian
HMHarry M. Mushlin
Harry M. Mushlin
SZSaman Zarbakhsh
Saman Zarbakhsh
GMGeorge Miller
George Miller
The transition of chronic pancreatic fibroinflammatory disease to neoplasia is a primary example of the paradigm linking inflammation to carcinogenesis. However, the cellular and molecular mediators bridging these entities are not well understood. Because TLR4 ligation can exacerbate pancreatic inflammation, we postulated that TLR4 activation drives pancreatic carcinogenesis. In this study, we show that lipopolysaccharide accelerates pancreatic tumorigenesis, whereas TLR4 inhibition is protective. Furthermore, blockade of the MyD88-independent TRIF pathway is protective against pancreatic cancer, whereas blockade of the MyD88-dependent pathway surprisingly exacerbates pancreatic inflammation and malignant progression. The protumorigenic and fibroinflammatory effects of MyD88 inhibition are mediated by dendritic cells (DCs), which induce pancreatic antigen–restricted Th2-deviated CD4+ T cells and promote the transition from pancreatitis to carcinoma. Our data implicate a primary role for DCs in pancreatic carcinogenesis and illustrate divergent pathways in which blockade of TLR4 signaling via TRIF is protective against pancreatic cancer and, conversely, MyD88 inhibition exacerbates pancreatic inflammation and neoplastic transformation by augmenting the DC–Th2 axis.

6 December 2021 in Cell
Verified
Journal Article
Closed access
ASAlexandra Schnell
Alexandra Schnell
LHLinglin Huang
Linglin Huang
MSMeromit Singer
Meromit Singer
ASAnvita Singaraju
Anvita Singaraju
RBRocky M. Barilla
Rocky M. Barilla
VKVijay K. Kuchroo
Vijay K. Kuchroo

21 June 2023 in Nature
Verified
Journal Article
Closed access
PDF file
LBLloyd Bod
Lloyd Bod
YKYoon-Chul Kye
Yoon-Chul Kye
JSJingwen Shi
Jingwen Shi
ETElena Torlai Triglia
Elena Torlai Triglia
ASAlexandra Schnell
Alexandra Schnell
VKVijay K. Kuchroo
Vijay K. Kuchroo